A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

Inclusion Criteria: * Within body mass index (BMI) range 18 to 38 kilogram per meter square (kg/m2), inclusive. Body weight \<=100 kg * Left ventricular ejection fraction (LVEF) \>= 55 percent (%) measured by echocardiogram (ECHO) * Negative test result for drugs of abuse * Negative test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen * Negative test for latent Tuberculosis (TB) infection by QuantiFERON® TB Gold * Agree to use contraception and will refrain from sperm donation Exclusion Criteria: * Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, respiratory, gastrointestinal, immunological, neurological, or psychiatric disorder; acute infection; or other unstable medical disease * History of moderate or severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins * Known sensitivity to recombinant hyaluronidase or other form of hyaluronidase * History or presence of atrial fibrillation * History of any clinically significant or clinically relevant cardiac condition * History or presence of clinically significant electrocardiogram (ECG) abnormalities * History of uncontrolled hypertension, hyperlipidemia, thyroid disorder, or diabetes * Family history of clinically significant and clinically relevant hypersensitivity, allergy, or severe cardiac diseases * History of previous anti-cancer treatments including pertuzumab, trastuzumab, anthracyclines, or any cardiotoxic drugs * History of active or latent TB, regardless of treatment history * Poor peripheral venous access * History or presence of any malignancy, with the exception of completely excised basal cell or squamous cell carcinoma of the skin